Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. 1997

D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, New York, USA.

OBJECTIVE To compare the pharmacokinetics of ceftibuten, cefixime, ceturoxime axetil, and cefaclor after oral administration. METHODS Randomized, four-period, crossover study. METHODS Hospital-based clinical research center. METHODS Healthy adult men and women volunteers. METHODS Single 400-mg doses of cefixime and ceftibuten, and 500-mg doses of cefuroxime axetil and cefaclor. RESULTS Serum concentrations were determined by high-performance liquid chromatography methods. The mean oral clearances of cefixime, cefuroxime axetil, and cefaclor were similar, ranging from 20.4-27.0 L/hour; clearance of ceftibuten was approximately 4-fold less, 5.45 L/hour. The serum half-lives of ceftibuten (2.35 hrs) and cefixime (2.38 hrs) were prolonged compared with those of cefuroxime axetil (1.30 hrs) and cefaclor (0.693 hr). These agents also differed in terms of time to maximum concentration, time to peak plasma level, area under the curve, and apparent volume of distribution, the last reflecting differences in biovailability. CONCLUSIONS Ceftibuten had a relatively high time to maximum concentration and long half-life, resulting in a 3.5-fold higher area under the curve than cefixime, cefuroxime axetil, and cefaclor. These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002433 Cefaclor Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-,Ceclor,Cefaclor Anhydrous,Cefaclor Monohydrate,Keclor,Lilly 99638,S-6472,S 6472,S6472
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077722 Ceftibuten A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections. 7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic acid,7432 S,7432-S,Cedax,SCH 39720,SCH-39720,SCH39720
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
March 1984, Antimicrobial agents and chemotherapy,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
September 1994, Journal of pharmaceutical sciences,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
November 2003, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
January 2013, Journal of clinical pharmacology,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
February 1995, Antimicrobial agents and chemotherapy,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
January 1991, Infection,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
January 1997, Fundamental & clinical pharmacology,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
December 1989, Archives of otolaryngology--head & neck surgery,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
January 2002, Medical science monitor : international medical journal of experimental and clinical research,
D E Nix, and W T Symonds, and J M Hyatt, and J H Wilton, and M A Teal, and P Reidenberg, and M B Affrime
July 2000, International journal of pharmaceutics,
Copied contents to your clipboard!